US/UK/Canada

Share

About Us

TikoMed is a privately held pharmaceutical company based in Sweden. TikoMed is developing innovative treatments for neurodegenerative diseases and other degenerative conditions through its drug candidate ILB®, a dextran sulfate that has shown a good safety profile and promising results for the treatment of ALS in limited phase 2a studies. For more information, see www.tikomed.com.

Links

Pick a time period -
Tags ( Active)

Oslo University Hospital begins ALS study with TikoMed’s drug candidate ILB[®]

PRESS RELEASE   Stockholm-Oslo 13 March, 2026 Oslo University Hospital has now begun the inclusion of patients in the IMPACT study, which aims to investigate the efficacy and safety of TikoMed’s candidate drug ILB® compared to riluzole for the treatment of ALS. TikoMed provides ILB® and placebo substance for the study. The study will include 120 patients from all over Norway and includes a randomized phase of 6 months where patients receive either ILB® or riluzole followed by a 6-month open-label phase where patients receive both medications. Therefore, after the initial six-

TikoMed signs letter of intent with Karolinska Institutet on myocardial infarction study

The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB[®] in myocardial infarction.PRESS RELEASE   Stockholm 25 February, 2026 The Department of Medicine Solna at Karolinska Institutet and TikoMed AB have signed a letter of intent for a collaboration on a clinical study of ILB® in myocardial infarction. The study is called ILBIAMI and the aim is to evaluate the effect of ILB® in counteracting the consequences of myocardial infarction by limiting the extent of heart muscle damage.

Oslo University Hospital to conduct randomized phase 2 trial of ILB® in ALS

Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, and will include 116 patients over a 12-month study period.Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Riluzole or ILB, followed by a 6-month open-label extension where patients will get both ILB and Riluzole. The study is sponsored by Oslo

TikoMed’s ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro

Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studiesViken, Sweden – 13[th] September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company’s lead drug candidate ILB® to: 1. inhibit infection of human cells by the NL63 coronavirus assessed by immunofluorescence of viral particles; and 2. directly block the interaction of the SARS-CoV-2 viral spike protein with the ACE2 receptor; and 3. modulate the downstream consequences of viral infection including the

TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action

Viken, Sweden – 7[th] September 2022 – TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company’s lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles. In the study, ILB® potently inhibited infection by all the strains of Dengue, Zika and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml.

TikoMed’s ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

Viken, Sweden – 31[st] August 2022 – TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed’s ILB® neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and

TikoMed Announces Appointment of Two Independent Directors

Viken – 17th August, 2022 – Today, Swedish biopharmaceutical company TikoMed AB announced the appointment of two new members to its Board of Directors, Tara Heitner and Pete Zorn. “We are excited to welcome Tara and Pete to our Board,” said Adam Bruce, Founder and Chairman of the Board of TikoMed. “Tara and Pete are perfect fits for our next steps with their strong track records of transactional experience. They bring years of organizational and business development expertise and leadership that will serve the company well as we aim to grow our business focused on the ILB® drug platform

TikoMed’s ILB® activates the body’s natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injury

Viken – 3rd August 2022 – A new study with TikoMed’s lead drug candidate, ILB®, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published in the International Journal of Molecular Sciences today. The data from the rodent model studying severe traumatic brain injury (sTBI), demonstrated that ILB® administration 30 minutes after sTBI prevents glutamate excitotoxicity and normalizes levels of amino acids involved in crucial brain metabolic functions. “The study shows the beneficial effect of ILB® on post-impact brain metabolism using a single dose of the

TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

Viken – 25th May, 2022 – A new study with TikoMed’s platform lead clinical drug candidate ILB®\,\[ ]provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The study was published in PLOS ONE today. In a Phase II study of ILB® administered to patients with ALS for five weeks, the progression of ALS was halted and/or reversed for all study participants assessed using the validated ALSFRS-R and Norris clincal rating scales that score a broad range of patient relevant

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®

Viken – 5[th] May, 2022 – Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical development, regulatory and commercial strategies. IQVIA brings together deep therapeutic expertise, unparalleled data, and technology alongside flexible operating models to enable

Tikomed's ILB® attenuates clinical symptoms and serum biomarkers of oxidative/nitrosative stress and mitochondrial dysfunction in ALS patients, data published by the Journal of Personalized Medicine

Viken – 16[th] August 2021 – New study results for Tikomed’s platform lead drug candidate ILB[® ]in the treatment of patients with amyotrophic lateral sclerosis (ALS), have now been published in the Journal of Personalized Medicine. The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB[®] treatment period. The treatment response appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (

First patient treated in TIKOMED’s Phase II study of clinical islet transplantation in patients with brittle diabetes

Viken – 12th February 2021 – TIKOMED, a specialty pharmaceutical company developing an infusion product for improving the outcome in cell therapies, today announced that the first patient has been treated in TIKOMED’s ongoing Phase II international, multicenter study – NNCIT-02.   In the NNCIT-02 study, brittle diabetes patients being transplanted with islets of Langerhans are treated with IBSOLVMIR® which has shown to be able to address the instant blood-mediated inflammatory reaction (IBMIR) occurring as an innate immune reaction to the infusion of transplanted cells. Previously, in

TIKOMED’S ILB ® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine

Viken – 7[ ]January 2021 – A new study on TIKOMED’s lead drug candidate, ILB[®], was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB[® ]leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB[®] to alleviate fibrotic diseases.  Professor Ann Logan, from the University of Warwick, leader of the research team and senior author of the publication, said, “Inflammation plays a vital role in healing, but when it becomes uncontrolled the immune system

TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants

Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.“This very important result of the beneficial effect of ILB® on post-impact brain metabolism was obtained using a single dose of the drug administered in a window of time compatible with clinical

TIKOMED granted Orphan Medicinal Drug Designation for ILB [® ]for the treatment of amyotrophic lateral sclerosis by the European Commission

Viken – 28[th] August 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than three to five years from symptom onset and for which there is yet no cure. Orphan Drug Designation (ODD) in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the

TIKOMED secures 5 M € funding for the clinical development of ILB™ and IBSOLVMIR®

Viken – 13th March 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that it has successfully completed a €5 million round of financing from current investors. The capital will primarily be used to support the ongoing clinical development program for ILB™ and IBSOLVMIR®, advancing the company’s position within the treatment of acute and degenerative neurological diseases and cell transplantation. “We are delighted to have secured this funding, which shows the confidence our shareholders have in our unique drug candidates and expertise”, said Anders

Locust Walk appointed Strategic and Business Development Advisor for the licensing process of ILB™

Viken – 9th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Locust Walk (LW) as strategic advisor and business development representative for the licensing process of ILB™.   “We are very pleased to secure this new collaboration as we have already worked closely with Locust Walk over the past twelve months, assessing our ILB™ portfolio and exploring our commercialization opportunities within different neurodegenerative disease areas such as ALS. With their proven track record and in-depth market insights in the field of

TIKOMED successfully closed fundraising of 8 Million Euros

Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB® program and the IBSOLVMIR® program. TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB® program) and an infusion product for improving outcomes in cell therapies (IBSOLVMIR® program). “I’m delighted that we have successfully completed our latest fundraising, which

First patient treated with ILB in TIKOMED’s clinical trial for ALS

Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden. Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well underway and that

Tikomed to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission

Viken, August 20[th], 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, has been granted permission by the UK Medicines and Healthcare products Regulatory Agency, for a phase II clinical trial of the company’s investigational drug ILB for patients with Amyotrophic Lateral Sclerosis (ALS), to be conducted at Birmingham University Hospital. Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that the UK Medicines and Healthcare products Regulatory

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe